Literature DB >> 15242536

gp340 (SAG) binds to the V3 sequence of gp120 important for chemokine receptor interaction.

Zhiwei Wu1, Ellis Golub, William R Abrams, Daniel Malamud.   

Abstract

Human saliva contains multiple components that inhibit HIV-1 infection in vitro, which may contribute to low oral HIV-1 transmission. Salivary agglutinin (SAG) is a high-molecular-weight glycoprotein encoded by DMBT-1 and identical to gp340, a member of the lung scavange receptor, cysteine-rich receptor family. gp340 binds to surfactants A and D, which is believed to function in the clearance of microorganisms from the lung, as part of the innate immune response. Previously we reported that SAG (gp340) specifically inhibits HIV-1 infection with broad activity against diverse HIV-1 isolates. This gp340 inhibitory activity is mediated by binding to viral gp120 and involves a region different from the CD4-binding site on gp120. Here, we report that the gp340-binding region is localized to a linear, highly conserved sequence near the stem of the V3 loop that is critical for chemokine receptor interaction during viral binding and infection. The interaction of gp340 with gp120 is enhanced by prebinding of sCD4 to gp120, suggesting that gp340 inhibitory activity is mediated by blocking access of the gp120 to the chemokine receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242536     DOI: 10.1089/0889222041217400

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

Review 1.  Antiviral activities in human saliva.

Authors:  D Malamud; W R Abrams; C A Barber; D Weissman; M Rehtanz; E Golub
Journal:  Adv Dent Res       Date:  2011-04

2.  The calcium-induced conformation and glycosylation of scavenger-rich cysteine repeat (SRCR) domains of glycoprotein 340 influence the high affinity interaction with antigen I/II homologs.

Authors:  Sangeetha Purushotham; Champion Deivanayagam
Journal:  J Biol Chem       Date:  2014-06-12       Impact factor: 5.157

3.  Salivary agglutinin and lung scavenger receptor cysteine-rich glycoprotein 340 have broad anti-influenza activities and interactions with surfactant protein D that vary according to donor source and sialylation.

Authors:  Kevan L Hartshorn; Antoon Ligtenberg; Mitchell R White; Martin Van Eijk; Max Hartshorn; Lily Pemberton; Uffe Holmskov; Erika Crouch
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

4.  Respiratory Deleted in Malignant Brain Tumours 1 (DMBT1) levels increase during lung maturation and infection.

Authors:  H Müller; C End; C Weiss; M Renner; A Bhandiwad; B M Helmke; N Gassler; M Hafner; A Poustka; J Mollenhauer; J Poeschl
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

Review 5.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

6.  An electrochemiluminescence assay for gp340 (DMBT1).

Authors:  Cheryl Barber; Drew Weissman; Kurt Barnhart; Minal Dalvi; William R Abrams; Daniel Malamud
Journal:  Anal Biochem       Date:  2013-05-30       Impact factor: 3.365

7.  gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue.

Authors:  Earl Stoddard; Houping Ni; Georgetta Cannon; Chunhui Zhou; Neville Kallenbach; Daniel Malamud; Drew Weissman
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

Review 8.  Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites.

Authors:  Antoon J M Ligtenberg; Niclas G Karlsson; Enno C I Veerman
Journal:  Int J Mol Sci       Date:  2010-12-17       Impact factor: 5.923

9.  Surfactant Protein D modulates HIV infection of both T-cells and dendritic cells.

Authors:  Jens Madsen; Gaurav D Gaiha; Nades Palaniyar; Tao Dong; Daniel A Mitchell; Howard W Clark
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

10.  Macroautophagy Regulation during HIV-1 Infection of CD4+ T Cells and Macrophages.

Authors:  Sophie Borel; Lucile Espert; Martine Biard-Piechaczyk
Journal:  Front Immunol       Date:  2012-05-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.